Zerhouni Retires, Sanofi's New R&D Chief John Reed Brings Early Research Experience From Roche
Sanofi's longtime head of R&D Elias Zerhouni will step down in July. He was a steady hand at Sanofi amid tumultuous leadership transitions, but his tenure was marked by hits and misses.
You may also be interested in...
The company is looking at deals in the $2bn to $5bn range, CEO Paul Hudson told investors, but premiums for assets are high and Sanofi is looking at earlier-stage opportunities as a result.
In CEO Paul Hudson's first earnings call at the company's helm, he said he has big goals for driving growth but a deeper strategic update will be outlined to investors on Dec. 10 in Cambridge, Mass.
Novartis’s erstwhile head of pharma will be tasked with making the French drug maker more agile on the commercial and research fronts and expanding its digital capabilities.